Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -23.40%. A quarter ago, it was expected that this company would post earnings of $0.47 per share when it actually produced earnings of $0.98, delivering a surprise of +108.51%.Over the last four quarters, the company ...

Core Insights - The Cooper Companies (COO) is currently more attractive to value investors compared to Merit Medical (MMSI) based on various financial metrics and rankings [1][3][7] Valuation Metrics - COO has a forward P/E ratio of 18.10, while MMSI has a forward P/E of 24.27, indicating that COO is potentially undervalued [5] - The PEG ratio for COO is 1.79, compared to MMSI's PEG ratio of 2.39, suggesting that COO has a better balance between price and expected earnings growth [5] - COO's P/B ratio is 1.77, significantly lower than MMSI's P/B of 3.51, further supporting the argument that COO is more attractively valued [6] Rankings and Grades - COO holds a Zacks Rank of 2 (Buy), while MMSI has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for COO [3] - The Value grade for COO is B, whereas MMSI has a Value grade of C, reflecting the superior valuation metrics of COO [6]

Core Viewpoint - Investors should closely monitor DENTSPLY SIRONA Inc. (XRAY) due to significant movements in the options market, particularly the high implied volatility of the Jan 16, 2026 $2.50 Call option [1] Company Analysis - DENTSPLY is currently rated as Zacks Rank 3 (Hold) in the Medical - Dental Supplies industry, which is positioned in the bottom 24% of the Zacks Industry Rank [3] - Over the last 60 days, there has been a mixed sentiment among analysts regarding earnings estimates; two analysts have raised their estimates while five have lowered theirs, resulting in a decrease of the Zacks Consensus Estimate for the current quarter from 47 cents per share to 46 cents [3] Options Market Insights - The high implied volatility surrounding DENTSPLY shares indicates that options traders are anticipating a significant price movement, which could be linked to an upcoming event that may trigger a rally or sell-off [2][4] - Seasoned options traders often seek out options with high implied volatility to sell premium, aiming to benefit from the decay of the option's value if the underlying stock does not move as much as expected by expiration [4]

Group 1: Earnings Performance - Cardinal Health reported quarterly earnings of $2.08 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and up from $1.84 per share a year ago, representing an earnings surprise of +2.46% [1] - The company posted revenues of $60.16 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.84%, but up from $59.87 billion year-over-year [2] Group 2: Stock Performance and Outlook - Cardinal shares have increased by approximately 33.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is $2.17 on revenues of $57.99 billion, and for the current fiscal year, it is $9.21 on revenues of $248.27 billion [7] Group 3: Industry Context - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Pro-Dex, Inc., another company in the same industry, is expected to report quarterly earnings of $0.47 per share, reflecting a year-over-year change of +2.2% [9]

The Zacks Medical - Dental Supplies industry in the Medical sector is reflecting weakness amid rising tariffs by the U.S. government on its trading partners, especially China. The tariffs are likely to stay and continue to impact industry sales for the rest of 2025, although several countries are negotiating a trade deal with the United States, which may lead to lower rates for specific countries. The tariffs are also leading to a rise in costs, disrupting supply chains and strategic supply shifts in the de ...

Key Takeaways CAH Q4 revenues are expected to rise 1.3% Y/Y to $60.67B on pharma volume and specialty strength.CAH EPS is projected at $2.03, up 10.3% Y/Y, aided by profit growth and share buybacks.CAH's medical segment recovery and at-home demand may offset macroeconomic headwinds.Cardinal Health, Inc. (CAH) is scheduled to report fourth-quarter fiscal 2025 results on Aug. 12, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.35 surpassed the Zacks Conse ...

Company Performance - Becton Dickinson (BDX) reported quarterly earnings of $3.68 per share, exceeding the Zacks Consensus Estimate of $3.42 per share, and showing an increase from $3.5 per share a year ago, representing an earnings surprise of +7.60% [1] - The company posted revenues of $5.51 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.47%, and up from $4.99 billion year-over-year [2] - Over the last four quarters, Becton Dickinson has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Outlook - Becton Dickinson shares have declined approximately 24% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $3.99 on revenues of $5.9 billion, and for the current fiscal year, it is $14.17 on revenues of $21.83 billion [7] Industry Context - The Medical - Dental Supplies industry, to which Becton Dickinson belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Becton Dickinson's stock performance [5]

While McKesson has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and ...

Company Performance - Staar Surgical reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.56, representing an earnings surprise of +87.50% [1] - The company posted revenues of $44.32 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.63%, although this is a decline from year-ago revenues of $99 million [2] - Over the last four quarters, Staar Surgical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Movement and Outlook - Staar Surgical shares have increased by approximately 11.2% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the earnings outlook for the upcoming quarters [3][4] - The current consensus EPS estimate for the next quarter is $0.18 on revenues of $87.83 million, while for the current fiscal year, it is -$0.78 on revenues of $258.21 million [7] Industry Context - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Staar Surgical's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Core Insights - Becton Dickinson and Company (BDX) is set to report its third-quarter fiscal 2025 results on August 7, with expectations of revenue growth despite a slight decline in earnings per share (EPS) [2][11][14]. BD Medical - The BD Medical segment is anticipated to see a revenue increase of 17.7% year over year, driven by the launch of the HemoSphere Alta Advanced Monitoring Platform and the BD neXus infusion pump [4][6][11]. - Management has confirmed progress in the Connected Care strategy, including 510(k) clearance for BD Alaris enhancements [5]. BD Life Sciences - The BD Life Sciences segment is projected to experience a revenue decline of 4.2% year over year, attributed to unfavorable market dynamics and slower recovery in blood culture testing [8][9]. - The global launch of the BD FACSDiscover A8 Cell Analyzer is expected to enhance product adoption and drive revenues [7]. BD Interventional - The BD Interventional segment's revenues are expected to rise by 2.9% year over year, supported by sustained demand and the launch of the Phasix ST hernia patch [11][13]. - The Phasix ST Umbilical Hernia Patch is noted as the first fully absorbable hernia patch specifically for umbilical hernias [12]. Financial Estimates - The overall revenue estimate for Q3 fiscal 2025 is $5.48 billion, reflecting a 9.9% increase from the previous year, while EPS is expected to decrease by 2.3% to $3.42 [11][14]. - The company has a forward 12-month price-to-earnings (P/E) ratio of 12.3X, which is lower than the industry average of 16.2X, indicating potential for growth [20][21]. Strategic Developments - BD plans to invest over $35 million to expand prefilled flush syringe manufacturing, which is expected to enhance production capacity [22][25]. - The company has submitted an application for a new at-home HPV test and received FDA clearance for the BD Veritor System for COVID-19, indicating ongoing innovation [26]. - A definitive agreement with Waters Corporation aims to combine their Biosciences & Diagnostic Solutions business, enhancing BD's strategic focus [27]. Market Performance - BD's shares have increased by 8.3% over the past three months, outperforming its peers in the Medical - Dental Supplies sector [17][19]. - The company is trading at a discount compared to its peers, suggesting potential for future growth if it aligns more closely with market performance [21][31].